摘要
目的筛选新型冠状病毒肺炎(COVID-19)症状相关的核心基因及信号通路,进而分析潜在的靶向药物。方法从文本挖掘数据库中获取与COVID-19主要症状相关的7个基因列表,取交集得到新的基因集。R软件进行基因功能注释和通路富集分析,Cytoscape软件可视化STRING数据库中的蛋白互作网络信息,并按分值筛选出核心基因,再通过DGIDB数据库分析基因与药物之间的作用关系,确定潜在的靶向药物。结果通过文本挖掘到97个与COVID-19症状相关的基因,其涉及的生物学过程主要为:Stat5蛋白酪氨酸磷酸化的正调控以及激活T细胞增殖的正向调控等;富集到的通路分别是细胞因子及其受体的相互作用、JAK-STAT信号通路和疟疾相关免疫反应等。最终通过基因-药物间的相互作用分析得到了9个密切相关的核心基因(即KIT、ACE、ESR1、TNF、VEGFA、IL1B、IL6、IL5、TGFB1),进而筛选到22个潜在药物。结论该研究通过大数据挖掘以及生物信息学分析方法对相关的基因进行功能注释以及通路分析,并通过基因药物之间的相互作用,筛选出一些与COVID-19症状相关的潜在药物,为COVID-19的对症治疗提供科学依据。
Objective To screen out core genes and signaling pathway related to COVID-19 symptoms and further analyze potential targeted drugs.Methods Seven gene lists related to main COVID-19 symptoms were obtained from the text mining database and a new gene set is obtained through intersection.Gene function annotation and pathway enrichment analysis was conducted with R software.Cytoscape was used to visualize the information of protein interaction network in the STRING database,and the core genes were screened out according to the value.Then,the drug-gene interaction was analyzed with the DGIDB database to determine the potential targeted drugs.Results Through text mining,97 genes related to COVID-19 symptoms were identified,and the main biological process involved was positive regulation of tyrosine phosphorylation of Stat5 protein and positive regulation of activation of T cell proliferation.The enriched pathways were the interaction of cytokines and their receptors,JAK-STAT signaling pathway and Malaria-associated immune response.Through the drug-gene interaction analysis,9 core genes closely related(KIT,ACE,ESR1,TNF,VEGFA,IL1B,IL6,IL5 and TGFB1)were obtained and then 24 related drugs were screened out.Conclusion In this study,functional annotation and pathway analysis is performed for related genes with big data mining and bioinformatics analysis and some potential drugs related to COVID-19 symptoms were screened out,providing scientific evidence for symptomatic treatment of COVID-19.
作者
李俊玲
何太平
王晓辉
杨峥嵘
LI Jun-ling;HE Tai-ping;WANG Xiao-hui;YANG Zheng-rong(School of Public Health,Guangdong Medical University,Dongguan 523808,China;School of Public Health,Guangdong Medical University,Zhanjiang 524023,China;Shenzhen Center for Disease Control and Prevention,Shenzhen 508055,China)
出处
《广东医科大学学报》
2021年第3期259-263,共5页
Journal of Guangdong Medical University
基金
深圳市科技创新委基础研究(No.JCYJ20180508152244835)
深圳市医学重点学科建设基金(No.SZXK064)。
